Enanta Pharmaceuticals | ENTA - Ebitda


Enanta Pharmaceuticals reported $-36.06M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Incyte USD 506.92M 74.6M Sep/2025
Insmed USD -297.13M 71.11M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 20.9M 61.44M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Novavax USD -117.12M 55.66M Sep/2024
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025